Trial Profile
A Twenty-Four Week, Open-Label, Non-Comparative, Multi-Center Study to Assess the Efficacy and Tolerability of an Aliskiren-Based Treatment Algorithm in Patients With Mild to Moderate Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2020
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual patient number (256) added as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual end date (Aug 2009 ) added as reported by ClinicalTrials.gov.